8-K current report · filed Oct 5, 2026

HARROW, INC. (HROW) 8-K Current Report: October 5, 2026

Item 1.01Item 2.01Item 7.01Item EX-99.1HROW overview

Short answer

HARROW, INC. (HROW) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). TYRVAYA acquisition scope narrowed: Viatris retains Japanese commercialization rights.

HARROW, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • TYRVAYA acquisition scope narrowed: Viatris retains Japanese commercialization rights
  • Closing cash consideration fixed at $30.0 million, eliminating net working capital adjustment uncertainty
  • Contingent milestone payments and other principal deal terms materially unchanged
  • Japan rights exclusion may limit Harrow’s future geographic revenue opportunity for TYRVAYA

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • TYRVAYA rights acquired globally excluding Japan, including regulatory approvals, intellectual property, technology, inventory and contracts
  • $30.0 million upfront cash payment, funded from cash on hand, reducing liquidity
  • Up to $70.0 million additional contingent milestones tied to net-sales thresholds through December 31, 2029
  • Japan opportunity retained through tiered royalties and planned collaboration with Viatris
  • Acquisition closed October 1, 2026, adding TYRVAYA commercialization obligations and potential revenue upside

Item 7.01 · Regulation FD Disclosure

  • Harrow completed its acquisition of the Acquired Assets on October 5, 2026
  • Exhibit 99.1 contains the acquisition announcement and transaction details for investor review

Item EX-99.1 · Exhibit EX-99.1

  • TYRVAYA acquisition closed for $30 million cash, with up to $70 million sales-based milestones, potential consideration $100 million
  • Worldwide rights acquired except Japan, with Viatris retaining Japan commercialization and paying Harrow royalties
  • TYRVAYA expected to contribute more than $30 million revenue in 2027
  • Approximately 40 Viatris personnel joining in Q4 2026, expanding Harrow’s ocular-surface commercial capacity
  • Portfolio now combines TYRVAYA and VEVYE, creating cross-selling and shared infrastructure opportunities in dry eye disease

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other HARROW, INC. 8-K filings

Get the next HROW 8-K as it lands

Follow HROW for push alerts, or ask the research agent what this filing means.